Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes |
Sep 2019 |
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Myelodysplastic Syndromes (MDS) |
Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria |
Mar 2021 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
Jun 2023 |
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
Oct 2023 |
Oncologist |
Myelodysplastic Syndromes (MDS) |
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
Apr 2023 |
The Oncologist |
Myelodysplastic Syndromes (MDS) |
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
Apr 2023 |
The Oncologist |
Myelodysplastic Syndromes (MDS) |
Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms |
Jul 2024 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab |
Aug 2020 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map |
Dec 2020 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |